Effect of Enalapril on the Progression of Chronic Renal Failure
Autor: | Anne-Lise Kamper, Paul P. Leyssac, Svend Strandgaard |
---|---|
Rok vydání: | 1992 |
Předmět: |
medicine.medical_specialty
biology business.industry medicine.medical_treatment Urology Renal function Angiotensin-converting enzyme urologic and male genital diseases medicine.disease female genital diseases and pregnancy complications law.invention Nephropathy Endocrinology Blood pressure Randomized controlled trial law Internal medicine Internal Medicine medicine biology.protein Enalapril Hemodialysis business Dialysis medicine.drug |
Zdroj: | American Journal of Hypertension. 5:423-430 |
ISSN: | 1941-7225 0895-7061 |
Popis: | In order to study the influence of angiotensin converting enzyme (ACE) inhibition on the progression of chronic nephropathy, 70 patients with a median glomerular filtration rate (GFR) of 15 (range, 6 to 54) mL/min/1.73 m2 were randomized in an open study to basic treatment with enalapril or conventional antihypertensive treatment. The patients were followed for at least 2 years or until they needed dialysis. The groups were comparable with respect to age and sex distribution, etiology of renal diseases, initial levels of renal function and arterial blood pressure (BP), and protein intake. The therapeutic goal was a BP of 120 to 140/80 to 90 mm Hg. The GFR, estimated by the plasma clearance of 51Cr-EDTA, was measured every third month, and the individual rate of progression was calculated as the slope of the GFR v time plot. In the enalapril group, the median decline in GFR was -0.20 (range, +0.18 to -7.11) mL/min/1.73 m2/month and in the control group it was -0.31 (+0.01 to -1.97) mL/min/1.73 m2/month (P less than .05). There was no significant difference in blood pressure or plasma lipid levels between the groups. Thus, the progression of moderate to severe chronic nephropathy was slower on a basic treatment with enalapril as compared to conventional antihypertensive therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |